FDA Biosimilar Action Plan: Could Improving Pharmacovigilance of Biologics Improve Patient and Physician Confidence in Biosimilars?

Expert Opinion on Drug Safety - United Kingdom
doi 10.1080/14740338.2020.1733966
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

FDA-Approved Biosimilar Insulin

Journal of diabetes science and technology
Internal MedicineEndocrinologyBioengineeringBiomedical EngineeringMetabolismDiabetes
2014English

Switching Between Biologics and Biosimilars in Inflammatory Bowel Disease

Clinical Gastroenterology and Hepatology
HepatologyGastroenterology
2019English

Correction To: FDA and EMA Biosimilar Approvals

Journal of General Internal Medicine
Internal Medicine
2019English

Biosimilars: Patient and Physician Acceptability Is the Fifth Hurdle to Market Competition

GaBI Journal
Drug GuidesPharmacy
2015English

FDA Approves First Biosimilar to Treat Cancer

Cancer Discovery
Oncology
2017English

Patient-Centred Care in Opioid Agonist Treatment Could Improve Outcomes

CMAJ
Medicine
2019English

Assessing Physician and Patient Acceptance of Infliximab Biosimilars in Rheumatoid Arthritis, Ankylosing Spondyloarthritis and Psoriatic Arthritis Across Germany

Patient Preference and Adherence
PharmacologyHealth PolicyMedicineToxicologySocial SciencesPharmaceutics
2017English

Improving Student Nurses' Confidence in Managing the Acutely Ill Patient

British Journal of Nursing
Nursing
2018English

Classification of Recombinant Biologics in the EU: Divergence Between National Pharmacovigilance Centers

BioDrugs
MedicineBiotechnologyPharmacology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy